Trimethobenzamide

From Wikipedia, the free encyclopedia


Trimethobenzamide
Systematic (IUPAC) name
N-{[4-(2-dimethylaminoethoxy)phenyl]methyl}- 3,4,5-trimethoxy-benzamide
Identifiers
CAS number	138-56-7
ATC code	?
PubChem	5577
DrugBank	APRD01277
Chemical data
Formula	C₂₁H₂₈N₂O₅
Mol. mass	388.458 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	7 to 9 hours (mean)
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	℞-only(US)
Routes	Oral, rectal, intramuscular

Trimethobenzamide is a medication frequently used as an antiemetic to prevent nausea and vomiting. It is often prescribed for patients with gastroenteritis, medication-induced nausea, and other illnesses. Trimethobenzamide is generally considered the most potent antiemetic that does not have effects on the serotonergic, dopaminergic, or histaminergic systems, so it has a lower likelihood of causing undesired side effects. In the United States, it requires a prescription.

1 Mechanism of action
2 Side effects
3 Formulations
4 References
5 External links

[edit] Mechanism of action

Although the specific mechanism through which trimethobenzamide functions is unknown, it is believed to affect the chemoreceptor trigger zone (CTZ) of the medulla oblongata.

[edit] Side effects

Possible side effects include drowsiness, dizziness, headache, diarrhea, muscle cramps, and blurred vision. More serious adverse effects include skin rash, tremors, parkinsonism, and jaundice.

[edit] Formulations

Trimethobenzamide is marketed under the brand names Tebamide and Tigan, manufactured by GlaxoSmithKline and King Pharmaceuticals, respectively. It is available as oral capsules and injectable formulations.

Trimethobenzamide was also available as a rectal suppository, but such formulations were banned by the U.S. Food and Drug Administration on April 6, 2007 due to unproven efficacy.^[1]